



Centre for
Heart Lung Innovation
UBC and St. Paul's Hospital

Centre for Heart Lung Innovation Research in Progress (R.I.P.)



Exploring the Effects of Inhaled Corticosteroid on the Airway Microbiome and Host Interphase in Chronic Obstructive Pulmonary Disease

William Yip
Masters Student
Drs Kelly McNagny & Don Sin

Monday, Nov 29th 2021
9:00 – 10:00 a.m.

Zoom Video Conference
(Meeting ID: 693 1997 7044; Passcode: 030679)

“Inhaled corticosteroids (ICS) are anti-inflammatory drugs used in the prevention and treatment of acute exacerbations in chronic obstructive pulmonary disease (COPD). Paradoxically, the use of ICS is also associated with an increased risk for pneumonia development in COPD patients. From a randomized controlled trial, our research group has recently shown that inhaled corticosteroids modifies the airway microbiome in COPD; however, the effects of ICS on the complex interactions between the lung microbiome and host epithelium remains unclear. In this presentation, we explore how longitudinal changes in the microbiome following ICS treatment may be related to longitudinal changes in gene expression by host epithelium and vice versa.”

This event is a Self-Approved Group Learning Activity as defined by the Maintenance Certification Program of the Royal College of Physicians and Surgeons of Canada



a place of mind

THE  LUNG ASSOCIATION™
British Columbia



HEART &
STROKE
FOUNDATION
OF BC & YUKON

Finding answers. For life.